Goldman Sachs Group Inc Corvus Pharmaceuticals, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$34.6 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$27.8 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$22.6 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$16.3 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$12.1 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $232M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...